Development of a COPD severity score

References

• Celli BR, Snider GL, Heffner J, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77–S120
   Web of Science ®Google Scholar
• Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1988 133;14–20
   Google Scholar
• Siafakas NM. ERS consensus statement: optimal assessment and management of chronic obstructive pulmonary disease. Eur Respir J 1996;6:270–5
   Google Scholar
• The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52 (Suppl 5):S4–S6
   Google Scholar
• Fabbri L, Caramori G, Beghe B, et al. Chronic obstructive pulmonary disease international guidelines. Curr Opin Pul Med 1998;4:76–84
   PubMedGoogle Scholar
• Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1256–76
   PubMedGoogle Scholar
• Fabbri L, Pauwels RA, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary updated 2003. COPD 2004;1: 105–41
   Google Scholar
• Ferguson GT, Enright PL, Buist AS, et al. Office spirometry for lung health assessment in adults. Chest 2000;117:1146–61
   PubMed Web of Science ®Google Scholar
• Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002;121:1434–40
   PubMed Web of Science ®Google Scholar
• Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856–61
   PubMed Web of Science ®Google Scholar
• Schols AMWJ, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1791–7
   PubMed Web of Science ®Google Scholar
• Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:591–7
   PubMed Web of Science ®Google Scholar
• Oga T, Mitsuhiro T, Sato S, et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:544–9
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. New Engl J Med 2004;350:1005–12
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W, and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–46
   Google Scholar
• Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study. J Am Med Assoc 1994;272:1497–505
   PubMed Web of Science ®Google Scholar
• Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 1980;93:391–8
   PubMed Web of Science ®Google Scholar
• Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. New Engl J Med 2003;348:2059–73
   PubMed Web of Science ®Google Scholar
• Streiner D, Norman G. Health measurement scales. A practical guide to their development and use; 1995
   Google Scholar
• The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New Engl J Med 2000;343:1902–9
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl C, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. New Engl J Med 1999;340:1948–53
   PubMed Web of Science ®Google Scholar
• Paggiaro PL, Dahle R, Bakran I, et al. Multicenter randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773–80
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PMA, Jones PW, et al. Randomised, double-blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000;320:1297–303
   PubMed Web of Science ®Google Scholar
• Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest 2001;119:1691–5
   PubMed Web of Science ®Google Scholar
• McCrory DC, Brown C, Gelfand SE, et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001;119:1190–209
   PubMed Web of Science ®Google Scholar
• Snow V, Lascher S, Mottur-Pilson C. The evidence base for management of acute exacerbations of COPD: clinical practice guideline, part 1. Chest 2001;119: 1185–9
   Google Scholar
• Eisner MD, Tropin L, Katz PP, et al. Development and validation of a survey-based COPD severity score. Chest 2005;127:1890–7
   PubMed Web of Science ®Google Scholar
• Burrows B, Knudson RJ, Cline MG, et al. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 1977;115:195–205
   PubMed Web of Science ®Google Scholar
• Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD. Chest 2000;117:662–71
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196–204
   PubMed Web of Science ®Google Scholar
• Grossman R, Mukherjee J, Vaughan D, et al. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 1998;113:131–41
   PubMed Web of Science ®Google Scholar
• Chodosh S, Shreurs A, Siami G, et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998;27:730–8
   Google Scholar
• Wilson R, Shentag JJ, Ball P, et al. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002;24: 639–52
   PubMed Web of Science ®Google Scholar
• Weiss LR. Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin Ther 2002;24:1414–25
   PubMed Web of Science ®Google Scholar
• Amsden GW, Baird IM, Simon S, et al. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003;123:772–7
   PubMed Web of Science ®Google Scholar
• Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. Morbid Mortal Week Rep 2002;51:1–7
   Google Scholar
• NIH Publication number 02–3659, Management segment (chapter 7). Global initiative for asthma. Global strategy for asthma management and prevention; 2002, updated 2004
   Google Scholar